TECHNOLOGY

10x Genomics Ordered to Pay $23.9 Million for Infringing Bio-Rad’s Patents

Case: The Federal District Court jury found that 10x willfully infringed three genetic analysis technology patents that Bio-Rad licensed from the University of Chicago on an exclusive basis. Specifically, the jury concluded that all single-cell and linked-read genomics products sold by 10x, including GemCode Long Read, Chromium Genome/Exome and Chromium Single Cell 3 willfully infringed the patented technology.

Significance: The court case is just one front in the IP war between the firms. 10x has filed a complaint with the International Trade Commission accusing Bio-Rad of illegally importing microfluidic systems violating its own patents into the US for sale. 10x also issued a statement expressing its strong disagreement with the court verdict and its intention to appeal.

CLOSE TO VIEW ARTICLE x

You have 3 articles left to view this month.

Your 3 Free Articles Per Month Goes Very Quickly!
Get a 3 month Premium Membership to
one of our G2 Newsletters today!

Click on one of the Newsletters below to sign up now and get unlimited access to all articles, archives, and tools for that specific newsletter!

Close

EMAIL ADDRESS


PASSWORD
EMAIL ADDRESS

FIRST NAME

LAST NAME

TITLE

COMPANY

PHONE

Try Premium Membership

(-00000g2)